{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T07:03:27Z","timestamp":1786863807306,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.ncl.2013.03.012","type":"journal-article","created":{"date-parts":[[2013,5,18]],"date-time":"2013-05-18T05:01:18Z","timestamp":1368853278000},"page":"869-878","source":"Crossref","is-referenced-by-count":17,"title":["Immunotherapy for Alzheimer\u2019s Disease"],"prefix":"10.1016","volume":"31","author":[{"given":"Martin R.","family":"Farlow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared R.","family":"Brosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ncl.2013.03.012_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006378.pub2","article-title":"Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer\u2019s disease","author":"Jaturapatporn","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"6514","key":"10.1016\/j.ncl.2013.03.012_bib2","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/373523a0","article-title":"Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein","volume":"373","author":"Games","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.ncl.2013.03.012_bib3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-\u03b2 attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.ncl.2013.03.012_bib4","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/01.WNL.0000148604.77591.67","article-title":"Evaluation of the safety and immunogenicity of synthetic AB42 (AN1792) in patients with AD","volume":"64","author":"Bayer","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2013.03.012_bib5","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of A(beta) immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ncl.2013.03.012_bib6","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/156720509787602852","article-title":"AN1792 (QS-21)-251 Study Team. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders","volume":"6","author":"Vellas","year":"2009","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.ncl.2013.03.012_bib7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after A(beta)42 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"issue":"9634","key":"10.1016\/j.ncl.2013.03.012_bib8","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of Abeta42 immunisation in Alzheimer\u2019s disease: follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ncl.2013.03.012_bib9","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A\u00a0phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2013.03.012_bib10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","article-title":"Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis","volume":"11","author":"Sperling","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ncl.2013.03.012_bib11","series-title":"A\u00a0randomized, double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with mild to moderate Alzheimer's disease who are apolipoprotein e \u03b54 non-carriers","author":"Salloway","year":"2012"},{"key":"10.1016\/j.ncl.2013.03.012_bib12","series-title":"A\u00a0randomized, double-blind, placebo-controlled clinical trial of intravenous bapineuzumab in patients with mild to moderate Alzheimer\u2019s disease who are apolipoprotein e \u03b54 carriers","author":"Sperling","year":"2012"},{"key":"10.1016\/j.ncl.2013.03.012_bib13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jalz.2011.09.224","article-title":"Safety and biomarker effects of solanezumab in patients with Alzheimer's disease","volume":"8","author":"Farlow","year":"2012","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.ncl.2013.03.012_bib14","series-title":"Phase 3 studies of solanezumab for mild to moderate Alzheimer's disease","author":"Doody","year":"2012"},{"issue":"5","key":"10.1016\/j.ncl.2013.03.012_bib15","first-page":"18","article-title":"Therapeutic effects of piracetam combined with intravenous immunoglobulin premature of Alzheimer type","volume":"107","author":"Kountouris","year":"2000","journal-title":"J\u00a0Neural Transm"},{"key":"10.1016\/j.ncl.2013.03.012_bib16","doi-asserted-by":"crossref","unstructured":"Dodel, R, Rominger A, Bartenstein P, et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. The Lancet online January 31, 2013. Available at: http:\/\/dx.doi.org\/10.1016\/S1474-4422(13)70014-0.","DOI":"10.1016\/S1474-4422(13)70014-0"},{"issue":"11","key":"10.1016\/j.ncl.2013.03.012_bib17","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.neurobiolaging.2007.12.021","article-title":"18-month study of intravenous immunoglobulin for treatment of mild Alzheimer\u2019s disease","volume":"30","author":"Relkin","year":"2009","journal-title":"Neurobiol Aging"},{"issue":"11","key":"10.1016\/j.ncl.2013.03.012_bib18","first-page":"A393","article-title":"A\u00a0double-blind, placebo-controlled, phase II clinical trial of intravenous immunoglobulin (IVIG) for treatment of Alzheimer\u2019s disease","volume":"70","author":"Relkin","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2013.03.012_bib19","doi-asserted-by":"crossref","unstructured":"Farlow MR, Dodel R, Jessen F, et\u00a0al. A randomized, double-blind, placebo-controlled dose-finding trial of intravenous immunoglobulin (Octapharma AG) in patients with Alzheimer\u2019s disease (GAM10-04). 63rd Annual Meeting of the American Academy of Neurology. Honolulu, April 10\u201315, 2011. P07.224, p. A620.","DOI":"10.1016\/j.jalz.2011.09.107"},{"key":"10.1016\/j.ncl.2013.03.012_bib20","series-title":"A\u00a0phase 3 study evaluating safety and effectiveness of immune globulin intravenous (IGIV 10%) for the treatment of mild to moderate Alzheimer\u2019s disease. [Clinicaltrials.gov identifier NCT00818662]","year":"2009"},{"issue":"Suppl 3","key":"10.1016\/j.ncl.2013.03.012_bib21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3233\/JAD-2011-0059","article-title":"Alzheimer\u2019s prevention initiative: a plan to accelerate the evaluation of presymptomatic treatments","volume":"26","author":"Reiman","year":"2011","journal-title":"J\u00a0Alzheimers Dis"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861913000388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861913000388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T19:16:06Z","timestamp":1563045366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861913000388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0733861913000388"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2013.03.012","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}